Etravirine in CSF is highly protein bound
Authors:
Open Access
- 20 January 2013
- journal article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 68 (5) , 1161-1168
Abstract
Etravirine has high affinity for plasma drug-binding proteins, such as albumin and α1-acid glycoprotein, which limits the amount of unbound etravirine available to enter the CNS. The objective of this study was to compare total and unbound etravirine concentrations in CSF with plasma concentrations and the in vitro median inhibitory concentration (IC50) for wild-type HIV (0.9 ng/mL). Total and bound etravirine concentrations were measured in 17 CSF and plasma pairs by isotope-dilution liquid chromatography tandem mass spectroscopy, radioligand displacement and ultracentrifugation. Unbound etravirine concentrations were calculated from the bound fraction. The dynamic range of the assay was 7.8–2000 (plasma) and 0.78–200 (CSF) ng/mL. Subjects were mostly middle-aged (median 43 years) white (78%) men (89%). All CSF etravirine concentrations were above the limit of quantification. Total and unbound median etravirine concentrations in CSF were 9.5 (IQR 6.4, 26.4) and 0.13 (IQR 0.08, 0.27) ng/mL, respectively. Etravirine was 96% (IQR 94.5, 97.2) protein bound in plasma and 98.4% (IQR 97.8, 98.8) in CSF. Total etravirine in CSF was 4.3% (IQR 3, 5.9) of total and 101% (IQR 76, 160) of unbound etravirine in plasma. There were no significant correlations between unbound etravirine concentrations and concentrations of albumin in plasma or CSF. Unbound etravirine concentrations in CSF did not reach the wild-type IC50 in any of the specimens. Unbound etravirine may not achieve optimal concentrations to inhibit HIV replication in the CNS.Keywords
This publication has 18 references indexed in Scilit:
- Pharmacokinetic Interactions between Etravirine and Non-Antiretroviral DrugsClinical Pharmacokinetics, 2011
- Efavirenz concentrations in CSF exceed IC50 for wild-type HIVJournal of Antimicrobial Chemotherapy, 2010
- Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trialsAntiviral Therapy, 2010
- Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performanceAIDS, 2009
- Quantification of etravirine (TMC125) in plasma, dried blood spots and peripheral blood mononuclear cell lysate by liquid chromatography tandem mass spectrometryJournal of Pharmaceutical and Biomedical Analysis, 2009
- Etravirine: A Second-Generation Nnrti for Treatment-Experienced Adults with Resistant HIV-1 InfectionFuture HIV Therapy, 2008
- Lopinavir with Ritonavir Reduces the HIV RNA Level in Cerebrospinal FluidClinical Infectious Diseases, 2007
- TMC125, a Novel Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor Active against Nonnucleoside Reverse Transcriptase Inhibitor-Resistant Human Immunodeficiency Virus Type 1Antimicrobial Agents and Chemotherapy, 2004
- Strategies for the Assessment of Matrix Effect in Quantitative Bioanalytical Methods Based on HPLC−MS/MSAnalytical Chemistry, 2003
- Cerebrospinal Fluid Human Immunodeficiency Virus Type 1 (HIV‐1) Suppression and Efavirenz Drug Concentrations in HIV‐1–Infected Patients Receiving Combination TherapyThe Journal of Infectious Diseases, 1999